announced that it is commencing recruitment of 215 patients for a Phase II clinical trial in relapsing-remitting multiple sclerosis (BioMS Medical clinical trials).

The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the ...